Moderna, Inc. — Director's Dealing 2020

Nov 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-11-16

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2020-11-16	Common Stock	M	10000	$19.15	Acquired	15000	Direct
2020-11-16	Common Stock	S	700	$94.42	Disposed	14300	Direct
2020-11-16	Common Stock	S	2895	$95.36	Disposed	11405	Direct
2020-11-16	Common Stock	S	4179	$96.44	Disposed	7226	Direct
2020-11-16	Common Stock	S	2623	$97.45	Disposed	4603	Direct
2020-11-16	Common Stock	S	3003	$98.34	Disposed	1600	Direct
2020-11-16	Common Stock	S	1600	$99.20	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-16	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct
2020-11-16	Stock Option (Right to Buy)	$19.15	M	10000	Disposed	2026-08-10	Common Stock (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.81 to $94.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.85 to $95.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.89 to $96.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.91 to $97.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.92 to $98.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.94 to $99.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

F9: This option is fully vested and exercisable.